Sen. Paul Wellstone
This article was originally published in The Gray Sheet
Executive Summary
Device industry loses a staunch advocate of neurological disease R&D funding, regulatory reforms and mental health parity with the death of the Minnesota Democrat in an Oct. 25 plane crash. As a member of the Senate HELP Committee, Wellstone supported the "Medical Device User Fee & Modernization Act" and introduced the "Medical Technology, Public Health & Innovation Act" of 1995, an FDA reform bill addressing Class III device issues. More recently, Wellstone raised concerns with FDA 510(k) regulation of implanted medical devices during incoming FDA Commissioner Mark McClellan's confirmation hearing...
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.